Physician profile
Constance E Thompson-Fly
NPI 1205184348
$1,238.23
in general payments reported to CMS, 2019-2025
13 companies · $384 in 2025
The $384 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $196 · 2022: $63.34 · 2023: $383 · 2024: $211 · 2025: $384.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $978.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $978.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $314.35 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $222.63 | 2021-2025 | Xifaxan, Trulance |
| Bayer Healthcare Pharmaceuticals INC. | $166.32 | 2023 | |
| Edwards Lifesciences Corporation | $141.55 | 2025 | |
| Novo Nordisk INC | $129.41 | 2023-2024 | Ozempic, Rybelsus |
| Genzyme Corporation | $96.63 | 2024 | |
| Novartis Pharmaceuticals Corporation | $45.18 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $26.00 | 2021 | |
| Calliditas Therapeutics US INC. | $22.00 | 2023 | Tarpeyo |
| Sanofi-Aventis U.S. LLC | $21.82 | 2021 | |
| Pfizer INC. | $19.00 | 2021 | |
| Shield Therapeutics INC | $16.74 | 2023 | Accrufer |
| Opko Pharmaceuticals, LLC | $16.60 | 2023 | Rayaldee |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Constance Thompson-Fly listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.